BioCentury
ARTICLE | Product Development

Why Loxo is leaning on internal discovery as Lilly’s R&D unit

Loxo is building a home-grown oncology pipeline, but it’s open to new technology deals

March 13, 2021 1:50 AM UTC

Loxo has expanded resources under Lilly’s wing and a new CEO at the helm, but it isn’t straying from the home-grown, concentrated pipeline strategy that made it successful as a biotech.

Jacob van Naarden, who stepped in as CEO of the Loxo Oncology unit of Eli Lilly and Co. (NYSE:LLY) after founding CEO Josh Bilenker departed last month, told BioCentury he plans to use the resources to build internal discovery and run a larger number of clinical programs in parallel, while still maintaining the strategy that brought two Loxo drugs from preclinical development to the market in seven years...

BCIQ Company Profiles

Eli Lilly and Co.